R&D Pipeline
Innovation R&D Pipeline
Potential of our proprietary technology platform to be expanded into more research and therapeutic areas in the near future.
Therapeutic Area Project Modality Indication Stage
Oncology
ALK201 ADC GC, BC, NSCLC,& solid tumors IND:2024 Q4
ALK202 Bispecific ADC NSCLC, HNC & solid tumors IND:2024 Q4
ALK101 Bispecific Antibody NSCLC, CRC,HCC & solid tumors IND:2025 Q2
ALKN204 Bispecific ADC Solid Tumors IND in the near future
ALKN203 ADC Solid Tumors IND in the near future
Immunology
ALKN401 Bispecific Antibody IgG associated diseases IND in the near future
Leveraging our powerful technology platform to drive continuous expansion of innovative pipeline